
Page#1
Consolidated income statement 
for the year ended 31 December 2020
2020 2019 2018 
Notes £m £m £m
Turnover 6 34,099 33,754 30,821
Cost of sales (11,704) (11,863) (10,241)
Gross profit 22,395 21,891 20,580
Selling, general and administration (11,456) (11,402) (9,915)
Research and development (5,098) (4,568) (3,893)
Royalty income 318 351 299
Other operating income/(expense) 7 1,624 689 (1,588)
Operating profit 8 7,783 6,961 5,483
Finance income 11 44 98 81
Finance expense 12 (892) (912) (798)
Profit on disposal of interest in associates – – 3
Share of after tax profits of associates and joint ventures 13 33 74 31
Profit before taxation 6,968 6,221 4,800
Taxation 14 (580) (953) (754)
Profit after taxation for the year 6,388 5,268 4,046
Profit attributable to non-controlling interests 639 623 423
Profit attributable to shareholders 5,749 4,645 3,623
6,388 5,268 4,046
Basic earnings per share (pence) 15 115.5p 93.9p 73.7p
Diluted earnings per share (pence) 15 114.1p 92.6p 72.9p
Consolidated statement of comprehensive income 
for the year ended 31 December 2020
2020 2019 2018 
£m £m £m
Profit for the year 6,388 5,268 4,046
Other comprehensive income/(expense) for the year
Items that may be subsequently reclassified to income statement:
Exchange movements on overseas net assets and net investment hedges 37 (59) (832) (480)
Reclassification of exchange movements on liquidation or disposal of overseas subsidiaries 37 36 (75) –
Fair value movements on cash flow hedges (19) (20) 140
Tax on fair value movements on cash flow hedges (18) 16 (22)
Reclassification of cash flow hedges to income statement 54 3 (175)
Deferred tax reversed on reclassification of cash flow hedges – – 20
(6) (908) (517)
Items that will not be reclassified to income statement:
Exchange movements on overseas net assets of non-controlling interests 37 (34) (75) (1)
Fair value movements on equity investments 1,348 372 180
Tax on fair value movements on equity investments (220) (95) 10
Remeasurement (losses)/gains on defined benefit plans (187) (1,050) 728
Tax on remeasurement of defined benefit plans 69 189 (146)
976 (659) 771
Other comprehensive income/(expense) for the year 37 970 (1,567) 254
Total comprehensive income for the year 7,358 3,701 4,300
Total comprehensive income for the year attributable to:
Shareholders 6,753 3,153 3,878
Non-controlling interests 605 548 422
Total comprehensive income for the year 7,358 3,701 4,300
154  GSK Annual Report 2020
Page#2
Strategic report
Governance and remuneration
Financial statements
Investor information
Consolidated balance sheet
as at 31 December 2020
2020 2019 
Notes £m £m
Non-current assets
Property, plant and equipment 17 10,176 10,348
Right of use assets 18 830 966
Goodwill 19 10,597 10,562
Other intangible assets 20 29,824 30,955
Investments in associates and joint ventures 21 364 314
Other investments 22 3,060 1,837
Deferred tax assets 14 4,287 4,096
Derivative financial instruments 43 5 103
Other non-current assets 23 1,041 1,020
Total non-current assets 60,184 60,201
Current assets
Inventories 24 5,996 5,947
Current tax recoverable 14 671 262
Trade and other receivables 25 6,952 7,202
Derivative financial instruments 43 152 421
Liquid investments 29 78 79
Cash and cash equivalents 26 6,292 4,707
Assets held for sale 27 106 873
Total current assets 20,247 19,491
Total assets 80,431 79,692
Current liabilities
Short-term borrowings 29 (3,725) (6,918)
Contingent consideration liabilities 32 (765) (755)
Trade and other payables 28 (15,840) (14,939)
Derivative financial instruments 43 (221) (188)
Current tax payable 14 (545) (629)
Short-term provisions 31 (1,052) (621)
Total current liabilities (22,148) (24,050)
Non-current liabilities
Long-term borrowings 29 (23,425) (23,590)
Corporation tax payable 14 (176) (189)
Deferred tax liabilities 14 (3,600) (3,810)
Pensions and other post-employment benefits 30 (3,650) (3,457)
Other provisions 31 (707) (670)
Derivative financial instruments 43 (10) (1)
Contingent consideration liabilities 32 (5,104) (4,724)
Other non-current liabilities 33 (803) (844)
Total non-current liabilities (37,475) (37,285)
Total liabilities (59,623) (61,335)
Net assets 20,808 18,357
Equity
Share capital 36 1,346 1,346
Share premium account 36 3,281 3,174
Retained earnings 37 6,755 4,530
Other reserves 37 3,205 2,355
Shareholders’ equity 14,587 11,405
Non-controlling interests 6,221 6,952
Total equity 20,808 18,357
The financial statements on pages 154 to 237 were approved by the Board on 8 March 2021 and signed on its behalf by
Sir Jonathan Symonds
Chairman
GSK Annual Report 2020  155
Page#3
Strategic report
Governance and remuneration
Financial statements
Investor information
Consolidated cash flow statement
for the year ended 31 December 2020
2020 2019 2018 
Notes £m £m £m
Cash flow from operating activities
Profit after taxation for the year 6,388 5,268 4,046
Adjustments reconciling profit after tax to operating cash flows 41 3,708 4,264 5,701
Cash generated from operations 10,096 9,532 9,747
Taxation paid (1,655) (1,512) (1,326)
Net cash inflow from operating activities 8,441 8,020 8,421
Cash flow from investing activities
Purchase of property, plant and equipment (1,226) (1,265) (1,344)
Proceeds from sale of property, plant and equipment 68 95 168
Purchase of intangible assets (1,013) (898) (452)
Proceeds from sale of intangible assets 1,255 404 256
Purchase of equity investments (411) (258) (309)
Proceeds from sale of equity investments 3,269 69 151
Contingent consideration paid (120) (113) (153)
Purchase of businesses, net of cash acquired 40 15 (3,571) –
Disposal of businesses 40 259 104 26
Investments in associates and joint ventures 40 (4) (11) (10)
Proceeds from disposal of interests in associates 40 – – 3
(Increase)/decrease in liquid investments (1) 1 –
Interest received 39 82 72
Dividends from associates, joint ventures and equity investments 31 7 39
Net cash inflow/(outflow) from investing activities 2,161 (5,354) (1,553)
Cash flow from financing activities
Issue of share capital 36 29 51 74
Purchase of non-controlling interests – (7) (9,320)
Increase in long-term loans 3,298 4,794 10,138
Repayment of short-term Notes (3,738) (4,160) (2,067)
(Repayment of)/increase in other short-term loans (3,567) 3,095 81
Repayment of lease liabilities (227) (214) (28)
Interest paid (864) (895) (766)
Dividends paid to shareholders (3,977) (3,953) (3,927)
Distributions to non-controlling interests (1,208) (364) (570)
Contributions from non-controlling interests 3 – 21
Other financing cash flows 119 (187) (25)
Net cash outflow from financing activities (10,132) (1,840) (6,389)
Increase in cash and bank overdrafts 42 470 826 479
Cash and bank overdrafts at beginning of year 4,831 4,087 3,600
Exchange adjustments (39) (82) 8
Increase in cash and bank overdrafts 470 826 479
Cash and bank overdrafts at end of year 5,262 4,831 4,087
Cash and bank overdrafts at end of year comprise:
Cash and cash equivalents 6,292 4,707 3,874
Cash and cash equivalents reported in assets held for sale – 507 485
6,292 5,214 4,359
Overdrafts (1,030) (383) (272)
5,262 4,831 4,087
GSK Annual Report 2019  157